#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.
Dr. Gayatri Devi, a neurologist specializing in memory disorders, discusses dementia as a spectrum, the evolving biology of Alzheimer's, and her personalized, multimodal approach to early detection and treatment, including anti-amyloid therapies and lifestyle interventions.
Deep Dive Analysis
16 Topic Outline
Introduction to Dr. Gayatri Devi's Practice and Philosophy
Dementia as a Spectrum: Alzheimer's Definition and Subtypes
Pathophysiology: Neuroinflammation, Amyloid, Tau Cascade
Role of Viral Infections and Oral Health in Neuroinflammation
Comprehensive Evaluation for Subtle Cognitive Decline
Differentiating Normal Forgetting from Concerning Language Issues
Women's Brain Health: Menopause, Estrogen, and Alzheimer's Risk
Biomarker Utility: Blood Tests, PET Scans, and Lumbar Puncture
Preclinical Screening and APOE4 Risk: A Case Study
Anti-Amyloid Therapies: Controversies, Efficacy, and ARIA Management
Multimodal Treatment Strategies for Alzheimer's Disease
Vascular and Lewy Body Dementias: Overlap and Diagnosis
Distinguishing and Treating Lewy Body Dementia
Menopause-Related Cognitive Impairment: Diagnosis and Treatment
Paradigm Shift: Alzheimer's Patients Can Improve
The Future of Dementia Care: AI, Precision, and Targeted Therapies
7 Key Concepts
Dementia Spectrum
An umbrella term for progressive loss of brain cell connectivity leading to functional decline, encompassing various types like Alzheimer's, vascular, and Lewy body dementia, which can present variably.
Alzheimer's Disease
A progressive loss of synaptic connections and function driven by extracellular amyloid plaques, intracellular neurofibrillary tau tangles, and neuroinflammation in the brain.
Cognitive Reserve
The brain's ability to maintain a large number of connections and be resilient to diseases like Alzheimer's, allowing high-functioning individuals to compensate for significant pathology.
Menopause-Related Cognitive Impairment (MERCI)
A condition where women experience memory and executive function deficits during menopause or perimenopause due to estrogen loss, with symptoms identical to early Alzheimer's, but treatable with hormone replacement.
Amyloid-Related Imaging Abnormalities (ARIA)
Side effects of anti-amyloid therapies, including brain edema (ARIA-E) and hemorrhage (ARIA-H), caused by the drugs clearing amyloid from blood vessel walls, disrupting their lining and causing leakage.
Lewy Body Dementia
A neurodegenerative disorder characterized by abnormal alpha-synuclein protein deposits, leading to motor symptoms (Parkinsonian features), fluctuating consciousness, cognitive impairment, and often visual hallucinations with preserved insight.
Alpha-Synuclein Spectrum Disorders
A concept that groups Lewy body dementia and Parkinson's disease, recognizing they share the same underlying alpha-synuclein pathology, with differences primarily in the timing and distribution of symptoms.
9 Questions Answered
Dementia is an umbrella term for progressive cognitive decline, while Alzheimer's disease is the most common type of dementia, specifically characterized by amyloid plaques, tau tangles, and neuroinflammation.
While traditionally thought to start with amyloid deposition, it's now understood that neuroimmunological (inflammatory) changes may predate amyloid, followed by tau pathology, ultimately leading to synaptic dysfunction over decades.
Forgetting names is common because names are inorganic pieces of information our brains are not optimized to store. However, struggling to recall common nouns or finding words to describe things is more problematic and can indicate cognitive decline.
Women's higher risk may be due to living longer past menopause (when estrogen, crucial for brain health, declines), surviving cardiovascular insults more often, and potential immunological factors.
Blood tests are promising but primarily standardized against amyloid PET scans. Since many older, asymptomatic individuals have amyloid, a positive blood test alone may not confirm Alzheimer's and should be followed by further testing.
The controversy stems from these drugs effectively clearing amyloid plaques but showing only small, sometimes insignificant, clinical benefits, while carrying risks of serious side effects like brain bleeding and swelling (ARIA).
Yes, contrary to past beliefs, some Alzheimer's patients can stabilize or even show improvement with personalized, multimodal treatment strategies, a realization made possible by biomarker-guided diagnosis.
Both involve alpha-synuclein pathology. Lewy body dementia presents with motor symptoms within a year of cognitive symptoms, whereas Parkinson's disease typically has motor symptoms for over a year before cognitive decline. The absence of a rest tremor is also a distinguishing clinical feature for Lewy body.
Treatment can include hormone replacement therapy (estrogen, with progesterone if needed), targeted brain exercises to combat 'learned non-use,' and cholinesterase inhibitors to address acetylcholine loss.
18 Actionable Insights
1. Adopt Anti-Inflammatory Lifestyle
Integrate anti-inflammatory activities into your daily routine, potentially as early as your 30s-40s, to prevent the cascade of Alzheimer’s pathology.
2. Prioritize Cardiovascular Health for Brain
Adopt practices that benefit cardiovascular health, as these are universally beneficial for brain health, irrespective of specific brain pathology.
3. Manage Viral Infections Proactively
Aggressively manage viruses like herpes simplex and varicella zoster, for instance, by getting a shingles vaccine if previously infected, to potentially reduce neuroinflammation and dementia risk.
4. Prioritize Oral Health for Brain
Maintain excellent gingival health to prevent inflammation in the gums, as this can negatively impact the brain through inflammatory pathways, increasing dementia susceptibility.
5. Consider Preclinical Alzheimer’s Testing Judiciously
Asymptomatic individuals should be cautious about preclinical Alzheimer’s testing unless they have a strong family history and high genetic risk (e.g., two APOE4 copies), due to potential misdiagnosis and psychological impact.
6. Slow Titration for High-Risk Anti-Amyloid Therapy
For individuals, especially APOE4/4 carriers, considering anti-amyloid therapies, advocate for a very slow titration protocol to significantly reduce the risk of severe side effects like brain bleeding and swelling.
7. Pre-medicate with Steroids for ARIA
For patients developing refractory ARIA (amyloid-related imaging abnormalities) during anti-amyloid therapy, especially APOE4/4 carriers, pre-medicating with steroids before subsequent doses can help control the inflammation and reduce complications.
8. Utilize Combination Drug Therapy
Employ a cocktail of medications, including cholinesterase inhibitors (e.g., donepezil, galantamine) and NMDA receptor antagonists (e.g., memantine), to manage Alzheimer’s symptoms and potentially slow progression.
9. Consider Targeted Transcranial Magnetic Stimulation (TMS)
Explore targeted TMS, guided by neuro-navigation, to stimulate specific brain regions (e.g., dorsolateral prefrontal cortex, Broca’s area) and maintain neuronal connectivity and function in dementia patients.
10. Manage Atrial Fibrillation Aggressively
For vascular dementia patients with atrial fibrillation causing strokes, consider procedures like a Watchman device to allow discontinuation of anticoagulants, reducing fall-related hemorrhage risk.
11. Discontinue Parkinson’s Drugs for Lewy Body
If diagnosed with Lewy body disease, work to discontinue Parkinson’s medications (e.g., levodopa, carbidopa) as they can worsen confusion and psychosis in Lewy body patients.
12. Engage in Targeted Brain Exercises
Actively engage in targeted brain exercises, even once a week, to combat ’learned non-use’ and dramatically recover function in areas affected by cognitive impairment, such as language or multitasking.
13. Consider Cholinesterase Inhibitors for Menopause-Related Cognitive Impairment
For women experiencing menopause-related cognitive impairment, cholinesterase inhibitors can be beneficial due to their mechanism of addressing acetylcholine loss in the brain.
14. Monitor Noun Recall, Not Just Names
Be more concerned about difficulty recalling common nouns (e.g., ‘chair,’ ‘book’) and finding descriptive words, as this is a more significant indicator of cognitive decline than merely forgetting names.
15. Believe in Alzheimer’s Improvement Potential
Recognize that, contrary to past conventional wisdom, some Alzheimer’s patients can improve with personalized treatment, a possibility now supported by biomarker-guided diagnosis.
16. Challenge Lewy Body Prognosis
Do not accept the misconception that Lewy body disease is rapidly progressive; patients often respond well to treatment, sometimes dramatically, and can have a life expectancy comparable to Alzheimer’s patients.
17. Accept Forgetting Names
Don’t worry excessively about forgetting names, as they are inorganic bits of information our brains are not optimally designed to retain, and it’s a common, non-pathological experience.
18. Embrace AI for Early Cognitive Detection
Stay open to future AI-assisted tools for early detection of subtle changes in thinking patterns, which are expected to significantly impact Alzheimer’s prevention.
5 Key Quotes
I feel like I'm in the field now almost as if I was an infectious disease doctor who is practicing medicine before and after penicillin was invented, you know, or discovered, sorry.
Dr. Gayatri Devi
Our brains are designed to forget most of the things we're exposed to most of the time, because that's how our brains function.
Dr. Gayatri Devi
I'm here to say that that is absolutely not true. Patients with Lewy body, in fact, respond fairly well to treatment and sometimes better than patients with Alzheimer's. Some patients actually get dramatically better.
Dr. Gayatri Devi
I never thought that patients with Alzheimer's could get better.
Dr. Gayatri Devi
There is no more heterogeneous disease I can think of, no more than Alzheimer's disease, because it's each person with Alzheimer's disease has their own private version of Alzheimer's disease that is different from everyone else who has the disease because that person has their own individual brain.
Dr. Gayatri Devi
2 Protocols
Slow Titration Protocol for Anti-Amyloid Therapy (Devi's Approach)
Dr. Gayatri Devi- Start anti-amyloid monoclonal antibody at a very low dose.
- Titrate up the dose very slowly over an extended period (e.g., taking two years to clear plaque instead of 1.5 years).
- Monitor patients rigorously with imaging (MRI) to detect amyloid-related imaging abnormalities (ARIA).
- If ARIA occurs and is refractory, pre-medicate with steroids before subsequent doses.
Comprehensive Cognitive Decline Evaluation (Devi's Practice)
Dr. Gayatri Devi- Conduct a meticulous general history, including immunological conditions, past viral exposures (e.g., shingles), and family history.
- Perform rigorous cognitive testing over several hours to uncover subtle problems, especially in high-functioning individuals.
- Assess brain electrophysiology for early slowing.
- Measure brain blood flow using transcranial Doppler.
- Conduct specialized MRI imaging with techniques to evaluate specific brain regions (hippocampus, parietal lobes).
- Perform amyloid and tau PET scans (or spinal tap for CSF analysis).
- Consider DAT scans to assess dopamine levels if other processes are suspected.
- Conduct extensive laboratory testing, including APOA, APOB, inflammatory markers, and APOE genotype.
- For early-onset family history, perform early-onset genetic screening.